Zymeworks Inc.
Zymeworks is a biotechnology company headquartered in Middletown, Delaware. It manages licensed healthcare assets and develops antibody-based therapies for conditions including cancer, inflammation and autoimmune disease. Its technology platforms include Azymetric for multispecific antibodies, drug conjugate platforms, EFECT and ProTECT. Zymeworks’ licensed portfolio includes Ziihera, a bispecific antibody approved in multiple jurisdictions for treating HER2-positive biliary tract cancer, and pasritamig, which is being studied for prostate cancer. Its wholly owned pipeline includes antibody-drug conjugate candidates ZW191 and ZW251 and multispecific antibody candidates ZW209 and ZW1528. Zymeworks earns payments through licensing and collaboration agreements, including milestone payments and royalties on product sales. Its partners include Jazz Pharmaceuticals and BeOne Medicines.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Zymeworks (ZYME) gained attention due to Phase 1 trial data for ZW191 in ovarian cancer and a licensing deal with Roche for ZW209. The stock has seen significant returns: 19.8% in 1 month, 28.2% in 3 months, 65.9% in 1 year, and 4x in 3 years. Analysts debate its valuation, with some seeing it as 27% undervalued at a fair value of $41.50, while others note its high P/B ratio of 26.6x compared to peers.
Ferring Pharmaceuticals agreed to acquire Gameto for $1.4B. Gilead Sciences will buy PepStar Therapeutics' oral IL-23R inhibitor program for $1.275B. Zymeworks partnered with Roche for T-cell engager ZW209. Astellas secured an option to license Audax Biosciences' immuno-oncology asset. Teva finalized a Medicaid cost-lowering agreement. Pfizer's Talzenna gained FDA approval for prostate cancer. Artiva Biotherapeutics laid off 94% of its workforce. Star Therapeutics raised $200M in funding.
Zymeworks presented updated trial results for ZW191, an ovarian cancer treatment, showing 65% and 55% response rates at 6.4 mg/kg and 9.6 mg/kg doses, respectively. The company plans to seek external funding for further development. Zymeworks also highlighted positive data from a partner's study of Ziihera in gastroesophageal cancer. Management discussed strategic plans for R&D, partnerships, and capital allocation.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning ZYME (Zymeworks Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent ZYME coverage spans financial news, corporate actions and technology.
In the last 30 days, ZYME insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($358K). The most active reporter was Schayowitz Adam, EVP, Head of R&D, with 1 filing.
Positive catalyst from early‑stage data and a major partnership.
Collaboration could boost Zymeworks' revenue and visibility.
Positive early‑stage data may lift Zymeworks' valuation as the program advances toward Phase 3.
Analyst upgrade and acquisition news likely support a price increase.
Positive catalyst from licensing deal and acquisition likely supports upside.
AlphAI scores every news story that mentions ZYME with an AI model for sentiment and relevance, and aggregates insider trades from Zymeworks Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Zymeworks (ZYME) gained attention due to Phase 1 trial data for ZW191 in ovarian cancer and a licensing deal with Roche for ZW209. The stock has seen significant returns: 19.8% in 1 month, 28.2% in 3 months, 65.9% in 1 year, and 4x in 3 years. Analysts debate its valuation, with some seeing it as 27% undervalued at a fair value of $41.50, while others note its high P/B ratio of 26.6x compared to peers.
Ferring Pharmaceuticals agreed to acquire Gameto for $1.4B. Gilead Sciences will buy PepStar Therapeutics' oral IL-23R inhibitor program for $1.275B. Zymeworks partnered with Roche for T-cell engager ZW209. Astellas secured an option to license Audax Biosciences' immuno-oncology asset. Teva finalized a Medicaid cost-lowering agreement. Pfizer's Talzenna gained FDA approval for prostate cancer. Artiva Biotherapeutics laid off 94% of its workforce. Star Therapeutics raised $200M in funding.
Zymeworks presented updated trial results for ZW191, an ovarian cancer treatment, showing 65% and 55% response rates at 6.4 mg/kg and 9.6 mg/kg doses, respectively. The company plans to seek external funding for further development. Zymeworks also highlighted positive data from a partner's study of Ziihera in gastroesophageal cancer. Management discussed strategic plans for R&D, partnerships, and capital allocation.
Truist Securities raised its price target for Zymeworks Inc. (NASDAQ:ZYME) to $35, citing pipeline progress and partnerships. The stock is up 53.6% over the past year, with a consensus Buy rating and 46% upside potential. Zymeworks recently acquired Theravance Biopharma and partnered with Roche for ZW209, with analysts highlighting positive developments and raising price targets.
Citizens reiterated a Market Outperform rating and $32 price target for Zymeworks (ZYME), citing clinical data on ZW191 and a Roche licensing deal. The stock is up 59% year-over-year. Zymeworks has $627.5M in cash and is conducting a share buyback. Other analysts have raised price targets, with Jefferies at $52 and H.C. Wainwright at $55.
Zymeworks Inc. (ZYME) presented clinical data for ZW191, an ovarian cancer drug, at ESMO 2026. The study showed a 64.5% response rate in high-grade serous platinum-resistant ovarian cancer patients at the 6.4 mg/kg dose, with a six-month progression-free survival rate of 61%. The company plans to discuss the results in a conference call on October 27, 2026.
Jefferies raised its price target on Zymeworks (NASDAQ:ZYME) to $52 from $50, maintaining a Buy rating after its licensing deal with Roche. The deal includes $55M upfront, $40M upon Phase 1b trial initiation, and up to $718M in milestone payments. Zymeworks' stock is currently at $28.30, up 63% over the past year. The company also completed its acquisition of Theravance Biopharma, which could generate over $100M in annual cash flow.
Zymeworks Inc. (ZYME) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3 ● Zymeworks to receive a $55 million upfront payment and a $40 million payment upon initiation of the Phase 1b trial, with potential for
Zymeworks Inc. (ZYME) appointed Suzanne Monahan as Senior Vice President, Commercial and General Manager for Theravance Biopharma. She will lead the commercial strategy for YUPELRI, a once-daily COPD treatment. Monahan has over 20 years of commercial leadership experience in the pharmaceutical industry.
Schayowitz Adam (EVP, Head of R&D) sold 13,832 shares of Zymeworks Inc. (ZYME) at $25.85 ($0.36M total) on 2026-10-09.
